GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (FRA:1HM) » Definitions » Cash Receipts from Operating Activities

Adaptive Biotechnologies (FRA:1HM) Cash Receipts from Operating Activities


View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies Cash Receipts from Operating Activities?

Cash Receipts from Operating Activities only applicable to companies reporting Cash Flow from Operations in direct method.


Adaptive Biotechnologies (FRA:1HM) Business Description

Industry
Traded in Other Exchanges
Address
1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").